Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
REGULATORY
US Chamber Raises Japan’s Pharma Policy as Unfair Trade Practice, Prods Federal Govt for Action
The US Chamber of Commerce has raised Japan’s pharmaceutical pricing as an “unfair trade practice” in a comment submitted to the federal government, calling for addressing the lack of transparency and predictability in the Japanese reimbursement system. The chamber particularly…
To read the full story
Related Article
- MHLW to “Listen to Industry Opinions” in Policymaking around CEA: Minister
March 13, 2025
- No Prior Talks with US Drug Makers for Deferred PMP Price Cuts: Health Minister
March 3, 2025
- Minister Touts “Balanced” Off-Year Revision after USCC Letter
February 19, 2025
- MHLW Not Yet Able to Examine Letters of Protest by US Lobbies: Minister
February 13, 2025
- US Lobbies Send Letters of Protest to Japan Embassy over Off-Year Revision, CEA
February 10, 2025
REGULATORY
- Japan to Clarify Non-Clinical Data Waivers for Repurposed Drugs, Ease Sakigake Rules
July 24, 2026
- Share of Negative-Margin WPPs Rises to 6.9%, Wholesalers Cite Communication Gap
July 24, 2026
- MHLW Unveils Preventive Healthcare Plan Focused on Dementia, Other Areas
July 24, 2026
- MHLW Eyes Limited Charge Exemptions for OTC-Like Topical Drugs
July 24, 2026
- MHLW Panel Voices Disappointment over Efluelda Launch Delay
July 24, 2026
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…